IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.
Pulmocide, a UK-based developer of therapies for serious acute and chronic respiratory diseases based on research at Imperial College London, secured $92m in series C commitments today from backers including commercialisation firm IP Group.
Investment company Jeito Capital led the oversubscribed round, which also attracted pharmaceutical firms Asahi Kasei Pharma, GlaxoSmithKline and Johnson & Johnson, the latter two through SR One and Johnson & Johnson Innovation – JJDC, respectively.
F-Prime Capital, an investment arm of financial services group…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
